Widening eligibility to phase II trials: constant arcsine difference phase II trialsA'HERN, Roger P.Controlled clinical trials. 2004, Vol 25, Num 3, pp 251-264, issn 0197-2456, 14 p.Article

The unclear zone in phase II clinical trialsALLEGRO, Sabrina; POND, Gregory R; HOTTE, Sébastien J et al.European journal of cancer (1990). 2010, Vol 46, Num 13, pp 2408-2413, issn 0959-8049, 6 p.Article

ONE-SAMPLE MULTIPLE TESTING PROCEDURE FOR PHASE II CLINICAL TRIALSFLEMING TR.1982; BIOMETRICS; ISSN 0006-341X; USA; DA. 1982; VOL. 38; NO 1; PP. 143-151; ABS. FRE; BIBL. 11 REF.Article

A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-lnduced neuromuscular blockGROUDINE, Scott B; SOTO, Roy; LIEN, Cynthia et al.Anesthesia and analgesia. 2007, Vol 104, Num 3, pp 555-562, issn 0003-2999, 8 p.Article

Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas = Essai phase II et pharmacocinétique de l'aziridinylbenzoquinone [2,5-dioziridinyl-3,6-bis(carboéthoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] dans les gliomes de grade élevéCURT, G. A; KELLEY, J. A; KUFTA, C. V et al.Cancer research (Baltimore). 1983, Vol 43, Num 12, pp 6102-6105, issn 0008-5472Article

CLINICAL STUDIES. V: RATIONALE, DESIGN, AND METHODOLOGY OF PHASE II CLINICAL TRIALSMUGOIA FM; MCGUIRE WP; PROZENCWEIG M et al.1979; METHODS CANCER RES.; USA; DA. 1979; VOL. 17; PP. 199-214; BIBL. 2 P.Article

An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced ParkinsonismPERENYI, A; BAGDY, G; ARATO, M et al.Pharmacopsychiatria. 1983, Vol 16, Num 5, pp 143-146, issn 0720-4280Article

A three-outcome design for phase II clinical trialsSARGENT, Daniel J; CHAN, Victor; GOLDBERG, Richard M et al.Controlled clinical trials. 2001, Vol 22, Num 2, pp 117-125, issn 0197-2456Article

Differential Roles of Phase I and Phase II Enzymes in 3,4-Methylendioxymethamphetamine-Induced CytotoxicityANTOLINO-LOBO, Irene; MEULENBELT, Jan; NIJMEIJER, Sandra M et al.Drug metabolism and disposition. 2010, Vol 38, Num 7, pp 1105-1112, issn 0090-9556, 8 p.Article

Novel Designs and End Points for Phase II Clinical Trials : Phase II Trials: Designs for the futureADJEI, Alex A; CHRISTIAN, Michaele; IVY, Percy et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1866-1872, issn 1078-0432, 7 p.Article

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALSLEVY, G; KAUFMANN, P; THOMPSON, J. L. P et al.Neurology. 2006, Vol 66, Num 5, pp 660-663, issn 0028-3878, 4 p.Article

Randomized phase II clinical trialsSIMON, R; WITTES, R. E; ELLENBERG, S. S et al.Cancer treatment reports. 1985, Vol 69, Num 12, pp 1375-1381, issn 0361-5960Article

Multiple Histology Phase II TrialsLEBLANC, Michael; RANKIN, Cathryn; CROWLEY, John et al.Clinical cancer research (Print). 2009, Vol 15, Num 13, pp 4256-4262, issn 1078-0432, 7 p.Article

THE MEASUREMENT OF THERAPEUTIC VALUEWARDELL WM; DIRADDO J; WEINTRAUB M et al.1980; J. CLIN. PHARMACOL.; USA; DA. 1980; VOL. 20; NO 2-3; PP. 77-90; BIBL. 32 REF.Article

Clinical drug development: an analysis of phase II trials, 1970-1985MARSONI, S; HOTH, D; SIMON, R et al.Cancer treatment reports. 1987, Vol 71, Num 1, pp 71-80, issn 0361-5960Article

PHASE II STUDY OF ANTINEOPLASTIC AGENTS IN JAPANMAJIMA H.1980; RECENT RESULTS CANCER RES.; DEU; DA. 1980; VOL. 70; PP. 61-65; BIBL. 7 REF.Conference Paper

Five-year change in statistical designs of phase II trials published in leading cancer journalsTHEZENAS, S; DUFFOUR, J; CULINE, S et al.European journal of cancer (1990). 2004, Vol 40, Num 8, pp 1244-1249, issn 0959-8049, 6 p.Article

Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpointsCAPRA, William B.Controlled clinical trials. 2004, Vol 25, Num 2, pp 168-177, issn 0197-2456, 10 p.Article

Optimising the design of phase II oncology trials : The importance of randomisationRATAIN, Mark J; SARGENT, Daniel J.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 275-280, issn 0959-8049, 6 p.Article

A short report on highlights of worldwide development of RIX4414 : A Singaporean experiencePHUA, K. B; QUAK, S. H; EMMANUEL, S et al.Vaccine. 2006, Vol 24, Num 18, pp 3782-3783, issn 0264-410X, 2 p.Conference Paper

Why we should be wary of single-center trialsBELLOMO, Rinaldo; WARRILLOW, Stephen J; READE, Michael C et al.Critical care medicine. 2009, Vol 37, Num 12, pp 3114-3119, issn 0090-3493, 6 p.Article

Effective Incorporation of Biomarkers into Phase II Trials : Phase II Trials: Designs for the futureMCSHANE, Lisa M; HUNSBERGER, Sally; ADJEI, Alex A et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1898-1905, issn 1078-0432, 8 p.Article

Design issues of randomized phase II trials and a proposal for phase II screening trialsRUBINSTEIN, Lawrence V; KORN, Edward L; FREIDLIN, Boris et al.Journal of clinical oncology. 2005, Vol 23, Num 28, pp 7199-7206, issn 0732-183X, 8 p.Article

How Should Phase II Trials in Cardiovascular Medicine Be Conducted ? SymposiumThe American heart journal. 2000, Vol 139, Num 4, pp S131-S210, issn 0002-8703Conference Proceedings

Selection of large and objectively measurable target lesions in EORTC phase II trials : impact on recruitment and response rateVAN GLABBEKE, M; VAN OOSTEROM, A. T; STEWARD, W et al.European journal of cancer. Part A. 1993, Vol 29, Num 14, pp 1943-1947Article